Expression of Mcm7 and Cdc6 in oral squamous cell carcinoma and precancerous lesions.

Department of Stomatology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Anticancer research (Impact Factor: 1.87). 01/2008; 28(6A):3763-9.
Source: PubMed

ABSTRACT The present study aimed at evaluating the clinical importance of Mcm7 and Cdc6 expression in oral squamous cell carcinoma (OSCC) and precancerous lesions.
RT-PCR and immunohistochemistry analysis were performed on 47 frozen samples and 98 paraffin-embedded samples to evaluate the mRNA and protein expressions of Mcm7 and Cdc6.
RT-PCR and immunohistochemistry indicated positive expressions of Mcm7 mRNA and protein in normal oral mucosa, precancerous lesions and OSCC. Significant differences were found between all the groups. Cdc6 mRNA and protein had low expressions in normal oral mucosa but were highly expressed in precancerous lesions and OSCC. Mcm7 and Cdc6 expressions in the lymph node metastasis cases were significantly higher than those of the nonmetastatic carcinomas.
High expressions of Mcm7 and Cdc6 are correlated with the development and metastasis of OSCC and may become a molecular marker for the early diagnosis and prognosis prediction for OSCC.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Epidermal growth factor receptor (EGFR) initiates a signaling cascade that leads to DNA synthesis and cell proliferation, but its role in regulating DNA replication licensing is unclear. Here, we show that activated EGFR phosphorylates the p56 isoform of Lyn, p56(Lyn), at Y32, which then phosphorylates MCM7, a licensing factor critical for DNA replication, at Y600 to increase its association with other minichromosome maintenance complex proteins, thereby promoting DNA synthesis complex assembly and cell proliferation. Both p56(Lyn) Y32 and MCM7 Y600 phosphorylation are enhanced in proliferating cells and correlated with poor survival of breast cancer patients. These results establish a signaling cascade in which EGFR enhances MCM7 phosphorylation and DNA replication through Lyn phosphorylation in human cancer cells.
    Cancer cell 06/2013; 23(6):796-810. · 25.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Norcantharidin (NCTD) is currently used for anticancer therapy but the exact mechanism of action remains unknown. Pre-replicative complexes (pre-RCs) are essential for cell DNA replication and highly related to malignant proliferation. Here, we examined the inhibitory effect of NCTD on pre-RC components in HepG2 cells. We showed that NCTD induced degradation of Cdc6 and Mcm2 in a dose-dependent manner. Under 100 μM NCTD concentration, about 70% of Cdc6 and 50% of Mcm2 were degraded. In addition, the nuclear translocation of Mcm6 was inhibited by NCTD. Further studies aiming at G1 synchronous cells showed that, NCTD reduced the chromatin-bound Cdc6, Mcm2 and Mcm6. Moreover, the cells were blocked from entering the S phase and accumulated at the G1 phase when released synchronously into the cell cycle. Consistently, the DNA replication was inhibited by NCTD. Finally, the combination NCTD with Cdc6 depletion lead to more severe cytotoxicity (88%) than NCTD (52%) and Cdc6 depletion (39%) alone. A synergic cytotoxicity was observed between Cdc6 depletion and NCTD. In conclusion, our results demonstrate that NCTD inhibits pre-RC assembly; subsequently blocks the G1 to S transition; and inhibits DNA replication in HepG2 cells. Pre-RCs are an intriguing target for cancer therapy, which merits further investigations for anticancer development.
    The American Journal of Chinese Medicine 01/2013; 41(3):665-682. · 2.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: MCM7 is one of the pivotal DNA replication licensing factors in controlling DNA synthesis and cell entry into S phase. Its expression and DNA copy number are some of the most predictive factors for the growth and behavior of human malignancies. In this study, we identified that MCM7 interacts with the receptor for activated protein kinase C 1 (RACK1), a protein kinase C (PKC) adaptor, in vivo and in vitro. The RACK1 binding motif in MCM7 is located at the amino acid 221-248. Knocking down RACK1 significantly reduced MCM7 chromatin association, DNA synthesis, and cell cycle entry into S phase. Activation of PKC by 12-O-tetradecanoylphorbol-13-acetate dramatically decreased MCM7 DNA replication licensing and induced cell growth arrest. Activation of PKC induced redistribution of RACK1 from nucleus to cytoplasm and decreased RACK1-chromatin association. The MCM7 mutant that does not bind RACK1 has no DNA replication licensing or oncogenic transformation activity. As a result, this study demonstrates a novel signaling mechanism that critically controls DNA synthesis and cell cycle progression.
    American Journal Of Pathology 01/2013; · 4.60 Impact Factor

Full-text (2 Sources)

Available from
Jun 4, 2014